 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
2 News |  |
- ||| LHC165 / Novartis, spartalizumab (PDR001) / Novartis
Trial termination, Combination therapy, Metastases: Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies (clinicaltrials.gov) - Aug 1, 2022
P1, N=45, Terminated, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Terminated; Business reasons
- || Review, Journal: Current status of intralesional agents in treatment of malignant melanoma. (Pubmed Central) - Jul 20, 2021
This review focuses on the current status of IT agents currently under clinical trials in melanoma. Reviewed therapies include T-VEC, T-VEC with immune checkpoint inhibitors including ipilimumab and pembrolizumab or other agents, RP1, OrienX010, Canerpaturev (C-REV, HF10), CAVATAK (coxsackievirus A21, CVA21) alone or in combination with checkpoint inhibitors, oncolytic polio/rhinovirus recombinant (PVSRIPO), MAGE-A3-expressing MG1 Maraba virus, VSV-IFNbetaTYRP1, suicide gene therapy, ONCOS-102, OBP-301 (Telomelysin), Stimulation of Interferon Genes Pathway (STING agonists) including DMXAA, MIW815 (ADU-S100) and MK-1454, PV-10, toll-like receptors (TLRs) agonists including TLR-9 agonists (SD-101, CMP-001, IMO-2125 or tilsotolimod, AST-008 or cavrotolimod, MGN1703 or lefitolimod), CV8102, NKTR-262 plus NKTR-214, LHC165, G100, intralesional interleukin-2, Daromun (L19IL2 plus L19TNF), Hiltonol (poly-ICLC), electroporation including calcium electroporation and plasmid interleukin-12 electroporation (pIL-12 EP), IT ipilimumab, INT230-6 (cisplatin and vinblastine with an amphiphilic penetration enhancer), TTI-621 (SIRPαFc), CD-40 agonistic antibodies (ABBV-927 and APX005M), antimicrobial peptide LL37 and other miscellaneous agents.
- || LHC165 / Novartis, spartalizumab (PDR001) / Novartis
Enrollment closed, Enrollment change, Combination therapy, Metastases: Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies (clinicaltrials.gov) - Apr 28, 2021
P1, N=45, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Reviewed therapies include T-VEC, T-VEC with immune checkpoint inhibitors including ipilimumab and pembrolizumab or other agents, RP1, OrienX010, Canerpaturev (C-REV, HF10), CAVATAK (coxsackievirus A21, CVA21) alone or in combination with checkpoint inhibitors, oncolytic polio/rhinovirus recombinant (PVSRIPO), MAGE-A3-expressing MG1 Maraba virus, VSV-IFNbetaTYRP1, suicide gene therapy, ONCOS-102, OBP-301 (Telomelysin), Stimulation of Interferon Genes Pathway (STING agonists) including DMXAA, MIW815 (ADU-S100) and MK-1454, PV-10, toll-like receptors (TLRs) agonists including TLR-9 agonists (SD-101, CMP-001, IMO-2125 or tilsotolimod, AST-008 or cavrotolimod, MGN1703 or lefitolimod), CV8102, NKTR-262 plus NKTR-214, LHC165, G100, intralesional interleukin-2, Daromun (L19IL2 plus L19TNF), Hiltonol (poly-ICLC), electroporation including calcium electroporation and plasmid interleukin-12 electroporation (pIL-12 EP), IT ipilimumab, INT230-6 (cisplatin and vinblastine with an amphiphilic penetration enhancer), TTI-621 (SIRPαFc), CD-40 agonistic antibodies (ABBV-927 and APX005M), antimicrobial peptide LL37 and other miscellaneous agents. Recruiting --> Active, not recruiting | N=80 --> 45
- || LHC165 / Novartis, spartalizumab (PDR001) / Novartis
Trial primary completion date, Combination therapy, Metastases: Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies (clinicaltrials.gov) - Mar 18, 2021
P1, N=80, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=80 --> 45 Trial primary completion date: Jun 2021 --> Jan 2022
- LHC165 / Novartis, spartalizumab (PDR001) / Novartis
[VIRTUAL] Phase I study of LHC165 ± spartalizumab (PDR001) in patients (pts) with advanced solid tumors () - Mar 11, 2021 - Abstract #AACR2021AACR_2547;
P1
Exposure to LHC165 increased with dose, no interaction was observed with spartalizumab. Increased systemic cytokines and T-cell inflammation after LHC165 suggests active TLR7 agonism.
- || LHC165 / Novartis, spartalizumab (PDR001) / Novartis
Enrollment change, Trial completion date, Combination therapy, Metastases: Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies (clinicaltrials.gov) - Jun 22, 2020
P1, N=80, Recruiting, Sponsor: Novartis Pharmaceuticals
Increased systemic cytokines and T-cell inflammation after LHC165 suggests active TLR7 agonism. N=200 --> 80 | Trial completion date: Dec 2021 --> Mar 2022
- ||| LHC165 / Novartis, spartalizumab (PDR001) / Novartis
New P1 trial, Combination therapy, Metastases: Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies (clinicaltrials.gov) - Jan 19, 2019
P1, N=200, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- | LHC165 / Novartis, spartalizumab (PDR001) / Novartis
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies (clinicaltrials.gov) - Oct 5, 2018
P1, N=200, Recruiting, Sponsor: Novartis Pharmaceuticals
N=200 --> 80 | Trial completion date: Dec 2021 --> Mar 2022 Trial completion date: Aug 2019 --> Dec 2021 | Trial primary completion date: Jun 2019 --> Apr 2021
- ||| LHC165 / Novartis, spartalizumab (PDR001) / Novartis
Enrollment open, Trial completion date, Trial primary completion date, Combination therapy, Metastases: Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies (clinicaltrials.gov) - Jun 7, 2018
P1, N=200, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Aug 2019 --> Dec 2021 | Trial primary completion date: Jun 2019 --> Apr 2021 Not yet recruiting --> Recruiting | Trial completion date: Feb 2021 --> Aug 2019 | Trial primary completion date: Feb 2021 --> Jun 2019